ClinicalTrials.gg
CompletedNCT00594204Updated Jul 20, 2010Results posted

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

A Phase 4 interventional study of varenicline tartrate (CP-526, 555-18) and Placebo in Smoking Cessation, sponsored by Pfizer. Completed at 41 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-07-20.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
593
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
25th of 110
593 · median 209
Started
2008
with 13 others
Phase 4
47 of 110
3 open now
Registered
19th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 25th largest by enrollment, is one of 14 that started in 2008, is one of 47 in phase 4, and was the 19th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current male or female cigarette smokers who are motivated to stop smoking.
  • Smoked an average of 10 cigarettes per day during past year and the month prior to first visit.

Exclusion criteria

Exclusion Criteria:

  • Patients who have used a nicotine replacement product, bupropion, clonidine or notriptyline within the past 6 months.
  • Patients currently with depression or diagnosed with depression in past 12 months.
  • Past or present history of psychosis, panic disorder, or bipolar disorder.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
593 participants (actual)

Study arms

  • Active comparator
    varenicline

    Drug: varenicline tartrate (CP-526, 555-18)

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • 1 mg twice a day for 12 weeks, starting with a 1-week titration period.

    Also known as: Chantix, Champix

  • DrugPlacebo

    matching placebo 1 tablet twice a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With 4-week Continuous Abstinence

    The number of participants who, at each visit from Week 9 through 12 (inclusive), reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \> 10 parts per milion (ppm) at any of these visits

    Time frame: Weeks 9 through 12

Secondary outcomes

  1. Number of Participants With Continuous Abstinence

    The number of participants who, at each contact from Week 9 through the given timepoint, reported no smoking and no use of other nicotine-containing products (Treatment Phase) or tobacco products (Nontreatment Phase) since the last study contact(on the Nicotine Use Inventory) and who did not have CO \> 10 ppm

    Time frame: Weeks 9 through 24

  2. Number of Participants With Seven-day Point Prevalence of Abstinence

    Number of participants who, at the given visit or telephone contact, reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) in the last 7 days and who did not have CO \>10 ppm on that day

    Time frame: Week 12 and 24

07

Results

Posted Jul 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started394199
Received treatment390198
Completed336154
Not completed5845
Withdrew: Adverse event153
Withdrew: Lost to follow-up95
Withdrew: Withdrawal by subject2329
Withdrew: Other43
Withdrew: Lack of efficacy34
Withdrew: Randomized but not treated41

Outcome measures

SecondaryNumber of Participants With Continuous Abstinence

The number of participants who, at each contact from Week 9 through the given timepoint, reported no smoking and no use of other nicotine-containing products (Treatment Phase) or tobacco products (Nontreatment Phase) since the last study contact(on the Nicotine Use Inventory) and who did not have CO \> 10 ppm

Time frame:
Weeks 9 through 24
Reported as:
Number · participants
Number of Participants With Continuous Abstinence
participantsVareniclinePlacebo
Number of Participants With Continuous Abstinence15526
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (p-values are obtained from a logistic regression model including the main effects of treatment and country) · Odds ratio (or): 4.78 · 95% CI 2.97 to 7.68Odds Ratios obtained from a logistic regression model including the main effects of treatment and country
SecondaryNumber of Participants With Seven-day Point Prevalence of Abstinence

Number of participants who, at the given visit or telephone contact, reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) in the last 7 days and who did not have CO \>10 ppm on that day

Time frame:
Week 12 and 24
Reported as:
Number · participants
Number of Participants With Seven-day Point Prevalence of Abstinence
participantsVareniclinePlacebo
Week 1222045
Week 2418538
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (p-values obtained from a logistic regression model including the main effects of treatment and country) · Odds ratio (or): 5.0 · 95% CI 3.3 to 7.5Odds ratios obtained from a logistic regression model including the main effects of treatment and country
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (p-values obtained from a logistic regression model including the main effects of treatment and country) · Odds ratio (or): 4.3 · 95% CI 2.8 to 6.5Odds ratios obtained from a logistic regression model including the main effects of treatment and country
PrimaryNumber of Participants With 4-week Continuous Abstinence

The number of participants who, at each visit from Week 9 through 12 (inclusive), reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \> 10 parts per milion (ppm) at any of these visits

Time frame:
Weeks 9 through 12
Reported as:
Number · participants
Number of Participants With 4-week Continuous Abstinence
participantsVareniclinePlacebo
Number of Participants With 4-week Continuous Abstinence20937
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.76 · 95% CI 3.74 to 8.88Odds Ratios obtained from a logistic regression model including the main effects of treatment and country

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—11/390 (2.8%)224/390 (57.4%)
Placebo—2/198 (1%)82/198 (41.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventVareniclinePlacebo
Suicidal ideationPsychiatric disorders2/3900/198
PeritonitisGastrointestinal disorders0/3901/198
AppendicitisInfections and infestations0/3901/198
DiverticulitisInfections and infestations0/3901/198
Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3901/198
BradycardiaCardiac disorders1/3900/198
PalpitationsCardiac disorders1/3900/198
HypersensitivityImmune system disorders1/3900/198
BronchitisInfections and infestations1/3900/198
LacerationInjury, poisoning and procedural complications1/3900/198
Most frequent other events
Showing 10 of 28
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders103/39016/198
HeadacheNervous system disorders64/39024/198
InsomniaPsychiatric disorders50/39013/198
AnxietyPsychiatric disorders16/39015/198
InfluenzaInfections and infestations14/39012/198
ConstipationGastrointestinal disorders23/39010/198
DizzinessNervous system disorders13/3909/198
SomnolenceNervous system disorders16/3909/198
CoughRespiratory, thoracic and mediastinal disorders10/3909/198
IrritabilityGeneral disorders17/3908/198

Baseline characteristics

Age, Customized
Age, Customized(years)VareniclinePlaceboTotal
< 55334164498
55 - 65492877
> 657613
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female16568233
Male225130355
08

Study locations

41 sites
  • Pfizer Investigational Site
    Porto Alegre, Centro RS, Brazil
  • Pfizer Investigational Site
    Fortaleza, CE 60864-190, Brazil
  • Pfizer Investigational Site
    Juiz de Fora, MG 36036-110, Brazil
  • Pfizer Investigational Site
    Botucatu, SP 18618-000, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04012-909, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04032-060, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 05019-010, Brazil
  • Pfizer Investigational Site
    Medellin, Antioquia 0, Colombia
  • Pfizer Investigational Site
    Barranquilla, Atlantico 0, Colombia
  • Pfizer Investigational Site
    San Pedro de Montes de Oca, San Jose, Costa Rica
  • Pfizer Investigational Site
    Cairo, Egypt
  • Pfizer Investigational Site
    Amman, Jordan
  • Pfizer Investigational Site
    Beirut Lebanon, 00000, Lebanon
  • Pfizer Investigational Site
    Beirut, Lebanon
  • Pfizer Investigational Site
    Mexico, D.f. 14000, Mexico
  • Pfizer Investigational Site
    Morelia, Michoacan 58249, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Pfizer Investigational Site
    Jeddah, 21499, Saudi Arabia
  • Pfizer Investigational Site
    Riyadh, 11211, Saudi Arabia
  • Pfizer Investigational Site
    Tygerberg, Cape Town 7505, South Africa
  • Pfizer Investigational Site
    Bloemfontein, Free State 9300, South Africa
  • Pfizer Investigational Site
    Benoni, Gauteng 1501, South Africa
  • Pfizer Investigational Site
    Midrand, Gauteng 1685, South Africa
  • Pfizer Investigational Site
    Tshwane, Gauteng, South Africa
  • Pfizer Investigational Site
    Soweto, Johannesburg, South Africa
  • Pfizer Investigational Site
    Durban, Kwazulu-Natal 4001, South Africa
  • Pfizer Investigational Site
    Sydenham, Durban, Kwazulu-natal 4091, South Africa
  • Pfizer Investigational Site
    Hillcrest, Pretoria 0083, South Africa
  • Pfizer Investigational Site
    Cape Town, Western Cape 7764, South Africa
  • Pfizer Investigational Site
    Paarl, Cape Town, Western Cape 7647, South Africa
  • Pfizer Investigational Site
    Durban, 4091, South Africa
  • Pfizer Investigational Site
    Lyttelton, 0140, South Africa
  • Pfizer Investigational Site
    Abu Dhabi, United Arab Emirates
  • Pfizer Investigational Site
    Al Ain, 0, United Arab Emirates
  • Pfizer Investigational Site
    Dubai, 0, United Arab Emirates
  • Pfizer Investigational Site
    Jumeirah/Dubai, 0, United Arab Emirates
  • Pfizer Investigational Site
    Ras Al Khaima, 0, United Arab Emirates
  • Pfizer Investigational Site
    Caracas, Distrito Capital 1011, Venezuela
  • Pfizer Investigational Site
    Barquisimeto, Lara 3002, Venezuela
  • Pfizer Investigational Site
    Gran Caracas, Miranda 1060, Venezuela
  • Pfizer Investigational Site
    Caracas, Venezuela
09

References and documents

Publications

  • Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, Park PW, Chopra P. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2011 Apr;33(4):465-77. doi: 10.1016/j.clinthera.2011.04.013. PubMed 21635992 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jun 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2008
First posted
Jan 15, 2008
Start
Apr 2008
Primary completionActual
Jun 2009
CompletionActual
Aug 2009
Results first posted
Jul 5, 2010
Last update
Jul 20, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00594204
Lead sponsor
Pfizer
First posted
Jan 15, 2008
Start date
Apr 2008
Primary completion
Jun 2009
Completion
Aug 2009
Results posted
Jul 5, 2010
Last update
Jul 20, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion